# Genprex, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Genprex, Inc.). ## Overview Genprex, Inc. is a clinical-stage gene therapy company developing gene-based treatments for cancer and diabetes. Its oncology programs use the ONCOPREX delivery system to deliver tumor suppressor genes, while its diabetes work centers on adeno-associated virus-based gene therapy licensed from the University of Pittsburgh. ## Products & services • ONCOPREX® Delivery System for oncology gene therapy • Acclaim-1 clinical program • Acclaim-3 clinical program • Gene therapy candidates for Type 1 and Type 2 diabetes • University of Pittsburgh-licensed Pdx1/MafA-based technology • Preclinical research and clinical development services - **Oncology gene therapy platform** (0%) — Systemic, non-viral gene therapy candidates and delivery technology for cancer. - **Diabetes gene therapy platform** (0%) — Licensed gene therapy programs targeting Type 1 and Type 2 diabetes. - **Clinical development programs** (0%) — Human trials and related regulatory work for lead oncology candidates. - **Preclinical research** (0%) — Animal-model and IND-enabling studies supporting future product candidates. - **Licensed technology and know-how** (0%) — Exclusive and non-exclusive rights from the University of Pittsburgh. - ONCOPREX® Delivery System for systemic oncology gene therapy - Acclaim-1 clinical trial program in oncology - Acclaim-3 clinical trial program in oncology - Type 1 and Type 2 diabetes gene therapy candidates - University of Pittsburgh-licensed Pdx1/MafA technology - Preclinical and clinical development of gene-based therapies ## Customers Genprex does not currently sell commercial products; its near-term counterparties are research institutions, clinical investigators, regulators, and manufacturing vendors that support development. If successful, its future customers would be oncology and diabetes patients, with commercialization likely occurring through partners or direct product sales after regulatory approval. - **Research collaborators** (primary) — Universities and scientific partners that perform animal-model and translational studies to advance the pipeline. - **Clinical trial participants and sites** (primary) — Patients and trial centers enrolled in Acclaim-1 and Acclaim-3 to generate efficacy and safety data. - **Regulatory authorities** (primary) — FDA and other agencies that must clear IND-enabling work and approve clinical advancement. - **Manufacturing and development vendors** (secondary) — Specialized third parties that support process scale-up, formulation, and clinical supply. - **Future commercial patients** (emerging) — Cancer and diabetes patients who would be treated if the company reaches approval and launch. - University research partners supporting diabetes and translational studies - Clinical trial sites and investigators running Acclaim-1 and Acclaim-3 - FDA and other regulators reviewing IND-enabling and clinical data - Manufacturing and process-development vendors for gene therapy supply - Future patients with cancer or diabetes, if products are approved ## Geography Genprex is headquartered in the United States and its development work is centered there, including clinical operations, regulatory interactions, and vendor management. The company also explicitly targets regulatory approval in Europe, and its diabetes licensing arrangement is worldwide, so future value creation depends on both U.S. and international development pathways. - United States is the core operating base and clinical-development center - FDA interactions are central because U.S. approval is the main near-term gate - Europe is a stated regulatory target for future product approval - Worldwide license rights expand the potential commercial footprint - No country revenue disclosed because the company has not generated product sales ## Strategy Genprex is prioritizing advancement of its lead oncology trials while continuing preclinical and IND-enabling work for diabetes and other potential programs. Management is also reducing operating costs, transitioning some manufacturing activities to new vendors, and exploring strategic alternatives and financing sources to preserve liquidity and extend runway. - **Complete enrollment and advance lead oncology trials** (short-term) — Clinical data are the main value driver and are needed for regulatory and partnering optionality. - **Advance diabetes program toward IND-enabling work** (medium-term) — The diabetes platform broadens the pipeline and could create a second development path. - **Preserve liquidity through cost reduction and financing** (short-term) — The company has no product revenue and depends on external capital to fund R&D. - **Optimize manufacturing and development execution** (medium-term) — Gene therapy programs require reliable, scalable manufacturing to support trials and future launch. - Advance Acclaim-1 and Acclaim-3 through enrollment and data readouts - Progress diabetes research toward IND-enabling studies and FDA meetings - Shift manufacturing to new vendors to improve scale and process capability - Reduce overhead and headcount to preserve cash - Pursue capital raises, collaborations, and strategic alternatives ## Risks Genprex is a pre-revenue biotech company with substantial clinical, regulatory, and financing risk. Its programs may fail in preclinical or clinical testing, may not obtain FDA or European approval, and may require more capital than it can raise on acceptable terms, which could force delays or program cuts. - **Going-concern and financing risk** [critical] — The company has recurring losses and no product sales, so it must raise capital to continue operations. - **Clinical trial failure** [high] — Lead programs are still in development and may not demonstrate sufficient efficacy or safety. - **Regulatory approval risk** [high] — FDA and other regulators may require additional studies or reject applications. - **Manufacturing and scale-up risk** [medium] — Gene therapy production is complex and vendor transitions can affect quality and timing. - **Nasdaq delisting risk** [high] — Failure to meet continued listing standards could impair liquidity and financing access. - No product revenue yet, so the business depends on external financing - Clinical trials may fail to show safety or efficacy - Regulatory approval is uncertain and time-consuming - Manufacturing changes can disrupt timelines and increase costs - Nasdaq listing compliance risk could reduce liquidity and access to capital ## Accounting The key accounting issue is the treatment of research and development costs, which are expensed as incurred and drive most of the company’s reported losses. Because Genprex has no product revenue, investors should also watch going-concern disclosures, share-based financing, and any fair-value or dilution effects from equity-linked capital raises. - **Research and development costs** — Clinical, preclinical, and manufacturing costs flow through earnings immediately - **Going-concern assessment** — Material disclosure affecting investor assessment of solvency - **Equity financing and dilution** — Common stock outstanding and capital structure - **Accruals and vendor-related estimates** — Expense timing and liabilities - R&D expense recognition is the main driver of reported losses - No product revenue means operating results depend on development spend - Going-concern assessment reflects reliance on future financing - Equity-line and ATM financing can create dilution and issuance costs - Vendor transitions may affect accruals, prepaid balances, and timing of expense --- *Last updated: 2026-04-28T20:11:12.385811+00:00*